/
JANX
$16.00-$0.67 (-4.02%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.0B
61M shares
52-week range
$12.12 – $35.34
17% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-13.35
Janux Therapeutics, Inc. Common Stock
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
www.januxrx.com- Employees
- 113
- IPO / List date
- Jun 11, 2021
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds JANX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in JANX as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded JANX yet.
